Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors

Journal of Biological Chemistry

Volumn 283, Issue 17, 2008, Pages 11424-11434

  Canals, Meritxell ^a   Milligan, Graeme ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOUDS; PHOSPHORYLATION; PROBABILITY DENSITY FUNCTION;

COEXPRESSED; EXPRESSION LEVELS; GUANOSINE; HEK293 CELLS; MAP KINASES; OPIOID RECEPTORS; TRIPHOSPHATE;

CHEMICAL REACTIONS;

ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; NALOXONE; RIMONABANT; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BENZOXAZINE DERIVATIVE; CANNABINOID; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE LOCUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR OCCUPANCY; BIOLOGICAL MODEL; CELL MEMBRANE; CHEMISTRY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; KINETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

BENZOXAZINES; CANNABINOIDS; CELL MEMBRANE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; KINETICS; LIGANDS; MODELS, BIOLOGICAL; MORPHOLINES; NALOXONE; NAPHTHALENES; PHOSPHORYLATION; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU;

EID: 45549109545     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M710300200     Document Type: Article

References (63)

1. Bjarnadottir, T. K., Gloriam, D. E., Hellstrand, S. H., Kristiansson, H., Fredriksson, R., and Schioth, H. B. (2006) Genomics 88, 263-273
2. Howlett, A. C. (2005) Handb. Exp. Pharmacol. 53-79
3. Childers, S. R., Fleming, L., Konkoy, C., Marckel, D., Pacheco, M., Sexton, T., and Ward, S. (1992) Ann. N. Y. Acad. Sci. 654, 33-51
4. Howlett, A. C. (1995) Annu. Rev. Pharmacol. Toxicol. 35, 607-634
5. Reisine, T., Law, S. F., Blake, A., and Tallent, M. (1996) Ann. N. Y. Acad. Sci. 780, 168-175
6. Waldhoer, M., Bartlett, S. E., and Whistler, J. L. (2004) Annu. Rev. Biochem. 73, 953-990
7. Pickel, V. M., Chan, J., Kash, T. L., Rodriguez, J. J., and MacKie, K. (2004) Neuroscience 127, 101-112
8. Rodriguez, J. J., Mackie, K., and Pickel, V. M. (2001) J. Neurosci. 21, 823-833
9. Salio, C., Fischer, J., Franzoni, M. F., Mackie, K., Kaneko, T., and Conrath, M. (2001) Neuroreport 12, 3689-3692
10. Christie, M. J. (2006) Br. J. Pharmacol. 148, 385-386
11. Navarro, M., Carrera, M. R., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gomez, R., del Arco, I., Villanua, M. A., Maldonado, R., Koob, G. F., and Rodriguez de Fonseca, F. (2001) J. Neurosci. 21, 5344-5350
12. Schoffelmeer, A. N., Hogenboom, F., Wardeh, G., and De Vries, T. J. (2006) Neuropharmacology 51, 773-781
13. Solinas, M., and Goldberg, S. R. (2005) Neuropsychopharmacology 30, 2035-2045
14. Tanda, G., Pontieri, F. E., and Di Chiara, G. (1997) Science 276, 2048-2050
15. Rios, C., Gomes, I., and Devi, L. A. (2006) Br. J. Pharmacol. 148, 387-395
16. Milligan, G. (2006) Drug Discov. Today 11, 541-549
17. Milligan, G. (2007) Biochim. Biophys. Acta 1768, 825-835
18. Hur, E. M., and Kim, K. T. (2002) Cell. Signal. 14, 397-405
19. Selbie, L. A., and Hill, S. J. (1998) Trends Pharmacol. Sci. 19, 87-93
20. Ellis, J., Pediani, J. D., Canals, M., Milasta, S., and Milligan, G. (2006) J. Biol. Chem. 281, 38812-38824
21. Milasta, S., Pediani, J., Appelbe, S., Trim, S., Wyatt, M., Cox, P., Fidock, M., and Milligan, G. (2006) Mol. Pharmacol. 69, 479-491
22. Canals, M., Jenkins, L., Kellett, E., and Milligan, G. (2006) J. Biol. Chem. 281, 16757-16767
23. Adie, E. J., Mullaney, I., McKenzie, F. R., and Milligan, G. (1992) Biochem. J. 285, 529-536
24. Mitchell, F. M., Buckley, N. J., and Milligan, G. (1993) Biochem. J. 293, 495-499
25. Mullaney, I., and Milligan, G. (1990) J. Neurochem. 55, 1890-1898
26. Lopez-Gimenez, J. F., Canals, M., Pediani, J. D., and Milligan, G. (2007) Mol. Pharmacol. 71, 1015-1029
27. Merkouris, M., Mullaney, I., Georgoussi, Z., and Milligan, G. (1997) J. Neurochem. 69, 2115-2122
28. Gardner, A., and Mallet, P. E. (2006) Eur. J. Pharmacol. 530, 103-106
29. MacLennan, S. J., Reynen, P. H., Kwan, J., and Bonhaus, D. W. (1998) Br. J. Pharmacol. 124, 619-622
30. Pertwee, R. G. (2005) Life Sci. 76, 1307-1324
31. Milligan, G. (2003) Mol. Pharmacol. 64, 1271-1276
32. Turu, G., Simon, A., Gyombolai, P., Szidonya, L., Bagdy, G., Lenkei, Z., and Hunyady, L. (2007) J. Biol. Chem. 282, 7753-7757
33. Lane, J. R., Powney, B., Wise, A., Rees, S., and Milligan, G. (2007) Mol. Pharmacol. 71, 1349-1359
34. Lane, J. R., Henderson, D., Powney, B., Wise, A., Rees, S., Daniels, D., Plumpton, C., Kinghorn, I., and Milligan, G. (2008) FASEB J., in press
35. Bidlack, J. M., and Parkhill, A. L. (2004) Methods Mol. Biol. 237, 135-143
36. Milligan, G. (2003) Trends Pharmacol. Sci. 24, 87-90
37. Abadji, V., Lucas-Lenard, J. M., Chin, C., and Kendall, D. A. (1999) J. Neurochem. 72, 2032-2038
38. Glass, M., and Felder, C. C. (1997) J. Neurosci. 17, 5327-5333
39. Milligan, G. (1994) Methods Enzymol. 237, 268-283
40. Nie, J., and Lewis, D. L. (2001) J. Neurosci. 21, 8758-8764
41. Tao, Q., and Abood, M. E. (1998) J. Pharmacol. Exp. Ther. 285, 651-658
42. Milligan, G., Ramsay, D., Pascal, G., and Carrillo, J. J. (2003) Life Sci. 74, 181-188
43. Vilardaga, J. P., Nikolaev, V. O., Lorenz, K., Ferrandon, S., Zhuang, Z., and Lohse, M. J. (2008) Nat. Chem. Biol. 4, 126-131
44. Gonzalez-Maeso, J., Ang, R., Yuen, T., Chan, P., Weisstaub, N. V., Lopez-Gimenez, J., Zhou, M., Okawa, Y., Callado, J. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., and Sealfon, S. C. (2008) Nature 452, 93-97
45. Hilairet, S., Bouaboula, M., Carriere, D., Le Fur, G., and Casellas, P. (2003) J. Biol. Chem. 278, 23731-23737
46. Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K., and Glass, M. (2005) Mol. Pharmacol. 67, 1697-1704
47. Leterrier, C., Laine, J., Darmon, M., Boudin, H., Rossier, J., and Lenkei, Z. (2006) J. Neurosci. 26, 3141-3153
48. McDonald, N. A., Henstridge, C. M., Connolly, C. N., and Irving, A. J. (2007) Mol. Pharmacol. 71, 976-984
49. Fraile-Ramos, A., Kohout, T. A., Waldhoer, M., and Marsh, M. (2003) Traffic 4, 243-253
50. Rosenkilde, M. M., Waldhoer, M., Luttichau, H. R., and Schwartz, T. W. (2001) Oncogene 20, 1582-1593
51. Vischer, H. F., Hulshof, J. W., de Esch, I. J., Smit, M. J., and Leurs, R. (2006) Ernst Schering Found. Symp. Proc. 2, 187-209
52. Roche, J. P., Bounds, S., Brown, S., and Mackie, K. (1999) Mol. Pharmacol. 56, 611-618
53. Kenakin, T. (2004) Mol. Pharmacol. 65, 2-11
54. Parra, S., and Bond, R. A. (2007) Curr. Opin. Pharmacol. 7, 146-150
55. Bosier, B., and Hermans, E. (2007) Trends Pharmacol. Sci. 28, 438-446
56. Galandrin, S., Oligny-Longpre, G., and Bouvier, M. (2007) Trends Pharmacol. Sci. 28, 423-430
57. Burt, A. R., Carr, I. C., Mullaney, I., Anderson, N. G., and Milligan, G. (1996) Biochem. J. 320, 227-235
58. Pierce, K. L., Luttrell, L. M., and Lefkowitz, R. J. (2001) Oncogene 20, 1532-1539
59. DeWire, S. M., Ahn, S., Lefkowitz, R. J., and Shenoy, S. K. (2007) Annu. Rev. Physiol. 69, 483-510
60. Ahn, S., Shenoy, S. K., Wei, H., and Lefkowitz, R. J. (2004) J. Biol. Chem. 279, 35518-35525
61. Gesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C. D., Wang, S., Eckhardt, A. E., Cowan, C. L., Spurney, R. F., Luttrell, L. M., and Lefkowitz, R. J. (2006) J. Biol. Chem. 281, 10856-10864
62. Macey, T. A., Lowe, J. D., and Chavkin, C. (2006) J. Biol. Chem. 281, 34515-34524
63. Salim, S., Standifer, K. M., and Eikenburg, D. C. (2007) J. Pharmacol. Exp. Ther. 321, 51-59